Neurocrine Biosciences
NBIX
NBIX
425 hedge funds and large institutions have $8.35B invested in Neurocrine Biosciences in 2022 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 161 increasing their positions, 144 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
5% more funds holding
Funds holding: 404 → 425 (+21)
0.87% more ownership
Funds ownership: 93.98% → 94.85% (+0.87%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Holders
425
Holding in Top 10
5
Calls
$89.6M
Puts
$79.5M
Top Buyers
| 1 | +$61.4M | |
| 2 | +$56.8M | |
| 3 | +$55.1M | |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$40.3M |
| 5 |
Two Sigma Advisers
New York
|
+$36.9M |
Top Sellers
| 1 | -$96.3M | |
| 2 | -$61.8M | |
| 3 | -$36.9M | |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$33.6M |
| 5 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$33.1M |